Last updated on April 19, 2014 at 18:42 EDT

DiagnoCure announces presentation on Previstage GCC at the 2013 ASCO annual meeting

May 16, 2013

New findings validate clinical utility in Colorectal Cancer Staging

MONTREAL, May 16, 2013 /PRNewswire/ – DiagnoCure Inc. (TSX: CUR) (OTCQX:
DGCRF) (the “Corporation”), today announced that results from a large
validation study of the Previstage(TM) GCC Colorectal Cancer Staging Test have been selected for presentation
at the 2013 American Society of Clinical Oncology((R)) (ASCO((R))) Annual Meeting, taking place in Chicago, Illinois from May 31 to June
4, 2013. The results of the second phase of the VITAR (Validating
Indicators To Associate Recurrence Risk) study, which included 463
untreated stage II (T3N0) colon cancer patients from North American and
European clinical sites will be presented during this annual meeting.
These patients had not been treated with adjuvant chemotherapy mainly
because their lymph nodes appeared cancer free by examination under the
microscope, yet 10% of them had a disease recurrence or died from
cancer afterwards.

The presentation titled “Guanylyl cyclase C (GCC) expression in lymph
nodes (LNs) as a determinant of recurrence in stage II colon cancer
(CC) patients (pts)” (Abstract #3639), will be exhibited on Sunday,
June 2, 8:00 AM – 11:45 AM, S Hall A2.

“Our new study supports the prognostic value of our Previstage(TM) GCC assay independently of traditional histopathology risk factors. In
order to establish a risk of recurrence for the stage II patients, the
study focused on the positive LN ratio (LNR), defined as the number of
nodes in which cancer cells were identified with the Previstage(TM) GCC test, divided by the total number of nodes examined,” said Dr Yves
Fradet, President and Chief Medical Officer of DiagnoCure. “We believe
that Previstage(TM) GCC has the potential to improve management of untreated stage II colon

About Colorectal Cancer and Previstage(TM) GCC

Every year in the United States and Canada, 165,000 people are diagnosed
with colorectal cancer. Of that number, 69,000 are considered at low
risk after surgery. Nonetheless, up to 20% of them suffer recurrence of
a more advanced cancer. To date, results of published studies totaling
over 1,000 patients have shown that, compared with traditionally-used
factors, the GCC biomarker is a better predictor of disease recurrence
in early stage colorectal cancer patients. Previstage(TM) GCC is currently the only colorectal cancer staging test that provides
prognostic information based on the tumor burden measured at the
molecular level in the lymph nodes. Tumor burden in the lymph nodes has
become more widely recognized by treating physicians as a key
prognostic factor to determine the risk of recurrence of cancer
patients, and hence, to determine which patients might benefit most
from adjuvant chemotherapy and which could be safely managed without

About DiagnoCure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high-value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. Previstage(TM) GCC is currently available for licensing. The Corporation has also
granted a worldwide exclusive license to Gen-Probe, now a wholly-owned
subsidiary of Hologic Inc. operating as Hologic Gen-Probe, for the
development and commercialization of a prostate cancer test using PCA3,
DiagnoCure’s proprietary molecular biomarker. Hologic Gen-Probe’s
PROGENSA(R) PCA3 test is commercialized in Europe under CE mark and is
approved for commercialization in Canada and the United States. For
more information, please visit www.diagnocure.com.

Forward looking statements

This release may contain forward looking statements that involve known
and unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. Forward-looking
statements can be identified by the use of the conditional or
forward-looking terminology such as “anticipates”, “assumes”,
“believes”, “estimates”, “expects”, “support”, “validate”, “intend”,
“may”, “plans”, “projects”, “should”, “will”, or the negative thereof
or other variations thereon. Forward-looking statements also include
any other statements that do not refer to historical facts. All such
forward-looking statements are made pursuant to the “safe-harbour”
provisions of applicable Canadian securities laws. By their very
nature, forward looking statements are based on expectations and
hypotheses and also involve risks and uncertainties, known and unknown,
many of which are beyond DiagnoCure’s control. Forward-looking
statements are presented for the purpose of assisting investors and
others in understanding certain key elements of the Corporation’s
current objectives, strategic priorities, expectations and plans, and
in obtaining a better understanding of the Corporation’s business and
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes and that they
should not place undue reliance on these forward looking statements.
For instance, any forward-looking statements regarding the outcome of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA(R) PCA3, are based on
management expectations and such outcome may vary materially depending
on global political and economic conditions, dependence on
collaboration partners, uncertainty of healthcare reimbursement, and
marketing and distribution challenges. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure’s most recent Annual Information Form under the heading
“Risk Factors”. DiagnoCure undertakes no obligation to publicly update
or revise any forward looking statements contained herein unless
required by the applicable securities laws and regulations.

SOURCE DiagnoCure inc.

Source: PR Newswire